Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of expanding the eligibility criteria for patients to take part in the Cancer Vaccine Launch Pad.

The NHS Cancer Vaccine Launch Pad (CVLP) is a platform set up to accelerate the development of cancer vaccines. After an assessment by the CVLP delivery group in May 2025, it was agreed to expand the eligibility of the CVLP to support cancer vaccines and immunotherapy clinical trials that require molecular or genomic testing. This expansion in scope means that more patients will have access to the benefits associated with CVLP trials. The platform is designed to be company and clinical trial agnostic, so any companies who are developing cancer vaccines or targeted immunotherapies can contact the CVLP to explore how the platform can support their research.